85% recurring revenue. 5x revenue growth in 5 years. The biotech royalty engine Wall Street forgot.
**TL;DR:** Halozyme ($HALO) licenses drug delivery tech that transforms hour-long IV infusions into 5-minute subcutaneous injections. 62% royalty revenue, 10 launched products with 20+ more in development, $781M owner earnings. The stock dropped 23% because GLP-1 competition is hurting some partner drugs. I think Wall Street is overreacting to a temporary headwind on a business with locked-in royalty growth. Trading at $67 vs. intrinsic value of $84 (20% margin of safety).
## The Business
HALO's ENHANZE platform is licensed to pharma giants including Roche, Johnson & Johnson, Pfizer, and Takeda. The technology uses an enzyme that temporarily opens tissue under the skin, allowing large drug volumes to be injected subcutaneously instead of IV. For patients, this means 5-minute injections instead of hour-long infusions.
What makes them sticky is the royalty model. Once a partner launches a drug using ENHANZE, Halozyme collects royalties for the life of the patent with almost no additional cost. 10 products are already launched and generating royalties. 20+ more are in development.
## The Numbers
| | |
|---|---|
| Operating Cash Flow | $677.42M |
| Stock-Based Compensation | -$57.53M |
| Smoothed CapEx (5yr avg) | -$13.62M |
| WC Adjustment | +$174.59M |
| **Owner Earnings** | **$780.86M** |
| Diluted Shares | 117.78M |
| **OE Per Share** | **$6.63** |
CapEx is minimal (0.90% of revenue) because this is a licensing business. No factories, no warehouses.
**Quality metrics:**
- Revenue Growth: +37.55% YoY
- Revenue Mix: 62% royalties, 25% device/API, 13% milestones
- Recurring Revenue: ~85%
- Net Debt: $1.83B (liquid assets: $319M)
- Buybacks TTM: $320M
## Why It's Cheap
The stock dropped 23% from its highs. Two things spooked Wall Street:
1. GLP-1 competition (Ozempic/Wegovy) is cannibalizing some partner drugs, particularly in the diabetes space.
2. Patent cliffs on major royalty contributors like Herceptin SC and Darzalex SC create uncertainty about future revenue.
## Why I Think The Market Is Wrong
The royalty pipeline is deep. 20+ drugs in development means new launches will offset patent expirations. The business model is capital-light with almost no incremental cost to collect royalties. Management is buying back $320M in stock, signaling they think shares are undervalued. At 10x owner earnings, you're paying a reasonable multiple for a business with 85% recurring revenue.
*Disclosure: I hold a position in HALO. Hard data from filings, AI-assisted writing, personal review and position. This is not financial advice.*